The US drug regulator Food and Drug Administration on Monday granted conditional approval to Aduhelm, an experimental new drug for the treatment of Alzheimer’s disease. This makes it the first drug to be approved by US regulators and the first new drug for the disease in nearly two decades. Developed by Biogen, the EduHelm is the first of its kind approved for Alzheimer’s disease and the first new treatment approved for Alzheimer’s since 2003. This raises hopes that thousands of people will be able to take advantage of this.

yahoo news According to a report, Alzheimer’s was first identified 115 years ago by a German psychiatrist, Alois Alzheimer. This disease is an irreversibly progressive brain disorder that gradually destroys the ability to remember and think. While the specific cause of Alzheimer’s disease is not fully known. Aduhelm is the first treatment of its kind approved for Alzheimer’s disease. Biogen is a Cambridge-based biotechnology company developed by its Japanese partner, Christian.

Also read – Waking up an hour earlier in the morning reduces the risk of depression by 23%

such agreement
The FDA said its approval was based on evaluating the effectiveness of Eduhelme in three separate studies representing 3,482 patients. At the same time, Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation, said, “There is a lot of public debate about whether the EduHelm should be approved. As is often the case with interpreting scientific data.

Also Read – Research Revealed: Here Are Eight Top Reasons People Watch Porn, You Know It Too

consent dispute
After FDA approval, some controversies also surfaced regarding this. Last November, ten of the 11 members of the FDA-appointed Peripheral and Central Nervous System Drug Advisory Committee voted against the drug’s approval based on submitted research.

.

LEAVE A REPLY

Please enter your comment!
Please enter your name here